AEterna Zentaris Completes Distribution of Remaining Shares of Atrium Biotechnologies
05-Jan-2007
AEterna Zentaris Inc. announced that it has completed the special distribution in kind of all of the 11,052,996 subordinate voting shares of the capital of Atrium Biotechnologies Inc. previously held by AEterna Zentaris by way of return of capital that was approved at the Company's special meeting of shareholders held on December 15, 2006.
Gilles Gagnon, AEterna Zentaris President and CEO commented, "Over the past year, not only did we successfully advance our pipeline to late-stage development, but we also set the stage to become a pure play biopharmaceutical company by spinning off Atrium. We are now extremely motivated and confident as we are more focused on building solid endocrinology and oncology franchises."
Other news from the department business & finance
